X4 Pharmaceuticals (XFOR) Consolidated Net Income (2017 - 2025)

X4 Pharmaceuticals' Consolidated Net Income history runs 9 years deep, the most recent figure standing at -$23.9 million for Q4 2025.

• Quarterly Consolidated Net Income rose 39.92% year-over-year to -$23.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$79.2 million (down 111.48% YoY) and the FY2025 annual result came in at -$79.2 million, down 111.48% from the prior year.
• Consolidated Net Income was -$23.9 million for Q4 2025 at X4 Pharmaceuticals, up from -$29.8 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
• A 5-year average of -$20.0 million and a median of -$22.9 million in 2022 frame the typical range for Consolidated Net Income.
• Peak annual rise in Consolidated Net Income reached 263.04% in 2024, while the deepest fall reached 1492.02% in 2024.
• X4 Pharmaceuticals' Consolidated Net Income stood at -$30.2 million in 2021, then increased by 3.65% to -$29.1 million in 2022, then jumped by 34.27% to -$19.1 million in 2023, then tumbled by 108.16% to -$39.8 million in 2024, then jumped by 39.92% to -$23.9 million in 2025.
• Business Quant data shows XFOR's Consolidated Net Income at -$23.9 million in Q4 2025, -$29.8 million in Q3 2025, and -$25.7 million in Q2 2025.